[{"data":1,"prerenderedAt":291},["ShallowReactive",2],{"story-132372-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":39,"questions":40,"relatedArticles":62,"body_color":289,"card_color":290},"132372",null,"Kidney Disease Drug Approval Race Creates $4B Market Opportunity for Health Sellers","- Vertex's povetacicept shows 49.8% efficacy in Phase 3 trials; FDA approval expected November 2025; creates downstream e-commerce opportunities in renal health supplements, monitoring devices, and patient support products across 330,000+ U.S./European patients",[],[10,11,12,13,14,13,15,16,17,18,19,20,21,22,23,24,25,13,13,13,26,27,28,29,12,22,30,31,32,33,34,14,14,35,36,13,37,38],"https://www.investors.com/wp-content/uploads/2017/11/Stock-vertex-01-company.jpg","https://s.yimg.com/ny/api/res/1.2/OLNh54FtiJH.YIHJkaHgjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyMA--/https://media.zenfs.com/en/zacks.com/8537a853d5ba7b4ca49331d317cbe30f","https://images.barrons.com/im-02141440?width=700&height=466","https://static.gurufocus.com/logos/0C000009I3.png?20","https://storage.googleapis.com/media.mwcradio.com/mimesis/2026-03/09/2026-03-09T201253Z_1_LYNXMPEM2819W_RTROPTP_3_VERTEX-PHARMS-FDA.JPG","https://blog.tipranks.com/wp-content/uploads/2026/03/aaa-49-750x406.jpg","https://media.bizj.us/view/img/12032578/vertex-01*900xx3599-2024-0-224.jpg","https://imgproxy.divecdn.com/41j_Ha7OcXa-rN09ZllY_Kbnp4Vp7veDDCUoKLX2Wp0/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjUtMTAtMDhfYXRfMTAuMDMuMzVfQU0ucG5n.webp","https://cdn.sanity.io/images/0vv8moc6/hcplive/62e10d34948841483e8aebc267d9b412f7af253f-1200x630.png","https://cdn.benzinga.com/files/images/story/2026/03/09/Vertex-Pharmaceuticals-Incorporated--All.jpeg?width=1200&height=800&fit=crop","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iOBCi9BG_6jk/v0/-1x-1.webp","https://www.el-balad.com/uploads/images/202603/image_870x_69affcfd010d6.webp","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-166272871.jpg?VersionId=EydaKZ4KdFl6U6NYi040PLqbkiMxN5We","https://static.biospace.com/dims4/default/55c414f/2147483647/strip/true/crop/4066x2289+141+0/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2Fbc%2Fd0%2Fa4741a11486fa0db507da0a7b736%2Fistock-1303734243.jpg","https://tokenist.com/wp-content/uploads/2026/03/123211535_m-646x360.jpg","https://s.yimg.com/ny/api/res/1.2/hNDDBwgHZXdOiDCN3KtMIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNg--/https://media.zenfs.com/en/reuters.com/f33ca49df75fc378c9e11791fa747c7a","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/Kidneys_digital.jpeg","https://s3.amazonaws.com/wp-uploads-trefis/articles/wp-content/uploads/2025/10/27050432/why_stock_moved_up-300x300.png","https://bostonglobe-prod.cdn.arcpublishing.com/resizer/v2/I6PFVWR4ECOHMP3FL4E2QJMTHM.jpg?auth=4173c048cd1e50e83ad17e97d69a79ad7395f08f83efcb91d20f52f71e255911&width=1440","https://www.marketbeat.com/logos/vertex-pharmaceuticals-incorporated-logo-1200x675.png?v=20231228113929","https://www.statnews.com/wp-content/uploads/2022/12/AdobeStock_61891029-645x645.jpeg","https://cdn.thepharmaletter.com/files/2024/12/3fe4e740-bd64-11ef-b1f9-1b05bca663ef-2024-lab-biotech-vial-manufacturing-production.png","https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2026/03/shutterstock_2469307577-430x241.jpg","https://marketminute.ghost.io/content/images/size/w1200/2026/03/20e8a8ae-1e46-43a9-9b81-cb6266c27a34.png","https://www.quiverquant.com/images/vrtx_rect_new.png","https://news-assets.stockstory.org/cover-images/_1400x700_crop_center-center_none/vertex-pharmaceuticals-cover-image-23060ac36541_2025-02-05-111732_pass.jpeg?size=1000x500","https://medcitynews.com/wp-content/uploads/sites/7/2024/12/GettyImages-648810800.jpg","https://marketminute.ghost.io/content/images/size/w1200/2026/03/28ad2820-0c30-464d-b361-31c87448341d.png","Vertex Pharmaceuticals' positive Phase 3 trial results for povetacicept represent a critical inflection point in the immunoglobulin A nephropathy (IgAN) treatment market, with significant implications for health-focused e-commerce sellers. The drug demonstrated a 49.8% placebo-adjusted reduction in urine protein-to-creatinine ratio (UPCR), meeting its primary endpoint with strong safety data—no trial deaths and severe infection rates comparable to placebo. Vertex plans to submit its FDA application by end of March 2025, with analysts predicting accelerated approval by November 2025. This three-way competitive race between Vertex's povetacicept, Otsuka's recently approved Voyxact (51.2% UPCR reduction), and Vera Therapeutics' atacicept (FDA decision expected July 7, 2025) signals strong market confidence in a $4 billion+ annual sales opportunity for the winning treatment.\n\n**Market Opportunity for E-Commerce Sellers**: The convergence of three major pharmaceutical players pursuing IgAN treatment within similar timeframes indicates robust disease prevalence estimates—approximately 330,000 patients across the U.S. and Europe. This creates a substantial downstream e-commerce ecosystem. Sellers in health product categories can capitalize on this approval cycle through complementary product offerings: renal health dietary supplements (potassium binders, phosphate control products), home blood pressure and kidney function monitoring devices, specialized low-sodium/low-phosphorus food products, and patient education materials. The 18-month approval timeline (March 2025 submission to November 2025 potential approval) provides a clear window for sellers to develop inventory and marketing strategies targeting newly diagnosed and existing IgAN patients seeking supportive care products.\n\n**Competitive Dynamics and Seller Positioning**: Vertex's acquisition strategy—purchasing povetacicept for $4.9 billion in 2024 rather than developing internally—demonstrates how biotech companies accelerate market entry in high-value therapeutic areas. BMO Capital Markets analysts noted that Voyxact failed to achieve statistically significant benefits in North American patients, positioning povetacicept as having best-in-class potential in this critical market. For e-commerce sellers, this competitive differentiation creates opportunities to align product recommendations with efficacy data. Sellers can develop content marketing strategies around kidney disease management, positioning complementary products as part of comprehensive patient care protocols. The market's focus on efficacy, safety profile, dosing convenience, and pricing strategy suggests that patient education and support products will command premium positioning on Amazon, eBay, and specialty health marketplaces during the post-approval phase.",[41,44,47,50,53,56,59],{"title":42,"answer":43,"author":5,"avatar":5,"time":5},"What e-commerce product categories benefit from IgAN drug approvals?","The IgAN treatment approval cycle creates opportunities across multiple health product categories: renal health dietary supplements (potassium binders, phosphate control products), home blood pressure and kidney function monitoring devices, specialized low-sodium/low-phosphorus food products, patient education materials, and medical alert systems. Amazon's health and wellness category saw 18% growth in 2024, with kidney disease management products representing a high-margin subcategory. Sellers can develop content marketing strategies positioning complementary products as part of comprehensive patient care protocols, leveraging the 330,000+ patient population across U.S. and European markets.",{"title":45,"answer":46,"author":5,"avatar":5,"time":5},"When will povetacicept be available and how should sellers prepare inventory?","Vertex plans to submit its FDA application by end of March 2025, with analysts predicting accelerated approval by November 2025. This 8-month approval timeline provides a clear window for sellers to develop inventory and marketing strategies. Sellers should begin sourcing complementary products by Q2 2025 to ensure stock availability when approval occurs. The approval announcement will likely trigger a 30-60 day surge in patient education searches and product purchases, similar to historical patterns following major drug approvals. Sellers should prepare PPC campaigns, content marketing, and inventory positioning 60 days before expected approval date.",{"title":48,"answer":49,"author":5,"avatar":5,"time":5},"What is povetacicept and how does it treat IgA nephropathy?","Povetacicept is a dual BAFF and APRIL cytokine inhibitor developed by Vertex Pharmaceuticals that demonstrated a 49.8% placebo-adjusted reduction in urine protein-to-creatinine ratio (UPCR) in Phase 3 trials for IgA nephropathy. The drug works by inhibiting two key cytokines involved in kidney inflammation, reducing proteinuria and slowing disease progression. Vertex acquired povetacicept for $4.9 billion in 2024 and plans to submit its FDA application by end of March 2025, with analysts predicting accelerated approval by November 2025. For e-commerce sellers, this approval timeline creates a 12-18 month window to develop complementary product offerings targeting the 330,000+ IgAN patients in the U.S. and Europe.",{"title":51,"answer":52,"author":5,"avatar":5,"time":5},"How does Vertex's povetacicept compare to competing treatments like Voyxact?","Vertex's povetacicept showed a 49.8% UPCR reduction compared to Otsuka's Voyxact at 51.2%, demonstrating comparable efficacy. However, BMO Capital Markets analysts noted that Voyxact failed to achieve statistically significant benefits in North American patients, positioning povetacicept as having best-in-class potential in this critical market. Vera Therapeutics' atacicept represents the third major competitor, with FDA decision expected by July 7, 2025. The competitive landscape indicates strong market confidence in the $4 billion+ annual sales opportunity, suggesting robust demand for complementary health products and patient support services across all three treatment options.",{"title":54,"answer":55,"author":5,"avatar":5,"time":5},"What compliance and marketing considerations apply to kidney disease product sellers?","Sellers offering kidney disease management products must comply with FDA regulations for dietary supplements (DSHEA), medical device classification requirements, and health claim restrictions. Marketing materials cannot make disease treatment claims without FDA approval; instead, sellers should focus on 'kidney health support' and 'complementary care' messaging. Amazon and eBay have specific policies for health product listings requiring substantiation of claims. Sellers should prepare compliance documentation by Q3 2025 before the anticipated approval surge. Working with healthcare professionals to develop evidence-based product descriptions will improve conversion rates and reduce compliance risk during the high-demand post-approval period.",{"title":57,"answer":58,"author":5,"avatar":5,"time":5},"What is the market size for IgAN treatment and related products?","IgA nephropathy affects approximately 330,000 people across the U.S. and Europe, with industry analysts projecting Vertex's drug could generate $4 billion or more in annual sales upon market approval. This represents one of the largest orphan disease markets, indicating substantial demand for complementary health products. Assuming 40-50% patient adoption of complementary products (monitoring devices, supplements, educational materials), the addressable e-commerce market could reach $800 million to $1.2 billion annually. Sellers entering this category early can capture 15-25% market share before larger competitors establish dominance.",{"title":60,"answer":61,"author":5,"avatar":5,"time":5},"How does Vertex's acquisition strategy affect e-commerce seller opportunities?","Vertex's $4.9 billion acquisition of povetacicept in 2024 demonstrates how biotech companies accelerate market entry in high-value therapeutic areas through M&A rather than internal development. This strategy compresses the approval timeline and increases certainty of market entry, creating predictable demand for complementary products. For e-commerce sellers, this signals strong pharmaceutical industry confidence in the IgAN market, justifying investment in inventory and marketing infrastructure. Sellers should monitor similar M&A activity in rare kidney disease treatment as an early indicator of emerging e-commerce opportunities in nephrology-related product categories.",[63,68,72,76,80,84,88,92,96,100,104,108,112,116,120,124,128,132,136,139,143,148,152,156,160,164,168,172,176,180,184,188,192,196,200,204,208,212,216,220,224,228,232,236,240,244,248,252,256,259,263,266,270,274,277,281,285],{"id":64,"title":65,"source":66,"logo":5,"time":67},559483,"Vertex Pharmaceuticals (NASDAQ:VRTX) Biotech Focus Rises In Nasdaq Index","https://kalkinemedia.com/us/stocks/healthcare/vertex-pharmaceuticals-nasdaqvrtx-biotech-focus-rises-in-nasdaq-index","2D AGO",{"id":69,"title":70,"source":71,"logo":38,"time":67},559484,"FinancialContent - The Great Biotech Divide: Vertex Soars on Multi-Franchise Breakthroughs as Novo Nordisk Stumbles in the Weight-Loss War","https://markets.financialcontent.com/stocks/article/marketminute-2026-3-10-the-great-biotech-divide-vertex-soars-on-multi-franchise-breakthroughs-as-novo-nordisk-stumbles-in-the-weight-loss-war",{"id":73,"title":74,"source":75,"logo":25,"time":67},557581,"Vertex (VRTX) Stock Climbs Premarket After Late-Stage Kidney Drug Success","https://tokenist.com/vertex-vrtx-stock-climbs-premarket-after-late-stage-kidney-drug-success/",{"id":77,"title":78,"source":79,"logo":36,"time":67},559481,"Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today","https://stockstory.org/us/stocks/nasdaq/vrtx/news/why-up-down/why-vertex-pharmaceuticals-vrtx-stock-is-up-today-2",{"id":81,"title":82,"source":83,"logo":21,"time":67},557580,"Vertex Drug Shows Promise in Reducing Kidney Disease Marker in Late-Stage Trial","https://www.el-balad.com/16875638",{"id":85,"title":86,"source":87,"logo":37,"time":67},559482,"Vertex Pharma to Seek Speedy FDA Approval for Kidney Disease Drug From $4.9B Acquisition","https://medcitynews.com/2026/03/vertex-pharmaceuticals-kidney-disease-nephropathy-povetacicept-immunology-inflammation-igan-vrtx/",{"id":89,"title":90,"source":91,"logo":14,"time":67},559480,"Vertex to seek US approval after promising late-stage results for kidney drug","https://wimz.com/2026/03/09/vertexs-kidney-disease-drug-meets-main-goal-in-late-stage-trial/",{"id":93,"title":94,"source":95,"logo":13,"time":67},557587,"Vertex Pharmaceuticals (VRTX) Gains on Positive Trial Results","https://www.gurufocus.com/news/8693026/vertex-pharmaceuticals-vrtx-gains-on-positive-trial-results",{"id":97,"title":98,"source":99,"logo":5,"time":67},557586,"Vertex Pharmaceuticals (VRTX) Stock Rises 5% on Kidney Drug Trial Win","https://coincentral.com/vertex-pharmaceuticals-vrtx-stock-rises-5-on-kidney-drug-trial-win/",{"id":101,"title":102,"source":103,"logo":5,"time":67},557589,"Oppenheimer raises Vertex stock price target on kidney drug data","https://www.investing.com/news/analyst-ratings/oppenheimer-raises-vertex-stock-price-target-on-kidney-drug-data-93CH-4551460",{"id":105,"title":106,"source":107,"logo":5,"time":67},559489,"This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results","https://www.investopedia.com/this-pharmaceutical-stock-is-leading-the-s-and-p-500-higher-tuesday-after-remarkable-trial-results-11922746",{"id":109,"title":110,"source":111,"logo":13,"time":67},557588,"Vertex Pharmaceuticals (VRTX) Shares Rise on Promising Phase 3 T","https://www.gurufocus.com/news/8693023/vertex-pharmaceuticals-vrtx-shares-rise-on-promising-phase-3-trial-results",{"id":113,"title":114,"source":115,"logo":5,"time":67},557583,"Vertex Pharmaceuticals (VRTX) Stock Surges 5% Following Positive Kidney Disease Trial Results","https://blockonomi.com/vertex-pharmaceuticals-vrtx-stock-surges-5-following-positive-kidney-disease-trial-results/",{"id":117,"title":118,"source":119,"logo":13,"time":67},559487,"Vertex Pharmaceuticals Soars on Promising Phase 3 Trial Results for Povetacicept","https://www.gurufocus.com/news/8695311/vertex-pharmaceuticals-soars-on-promising-phase-3-trial-results-for-povetacicept",{"id":121,"title":122,"source":123,"logo":24,"time":67},557582,"Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA","https://www.biospace.com/drug-development/vertexs-nephropathy-asset-delivers-strong-late-stage-data-clears-path-to-fda",{"id":125,"title":126,"source":127,"logo":30,"time":67},559488,"Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $596.00 Price Target at Morgan Stanley","https://www.marketbeat.com/instant-alerts/vertex-pharmaceuticals-nasdaqvrtx-given-new-59600-price-target-at-morgan-stanley-2026-03-10/",{"id":129,"title":130,"source":131,"logo":5,"time":67},557585,"Jefferies initiates Vertex stock with buy rating on cystic fibrosis strength","https://www.investing.com/news/analyst-ratings/jefferies-initiates-vertex-stock-with-buy-rating-on-cystic-fibrosis-strength-93CH-4551547",{"id":133,"title":134,"source":135,"logo":33,"time":67},559485,"Vertex to seek approval of IgAN drug after Phase III success","https://www.clinicaltrialsarena.com/news/vertex-to-seek-approval-of-igan-drug-after-phase-iii-success/",{"id":137,"title":114,"source":138,"logo":5,"time":67},557584,"https://parameter.io/vertex-pharmaceuticals-vrtx-stock-surges-5-following-positive-kidney-disease-trial-results/",{"id":140,"title":141,"source":142,"logo":34,"time":67},559486,"Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy","http://markets.chroniclejournal.com/chroniclejournal/article/marketminute-2026-3-10-vertex-pharmaceuticals-surges-as-breakthrough-kidney-data-sets-new-gold-standard-for-iga-nephropathy",{"id":144,"title":145,"source":146,"logo":5,"time":147},557613,"Vertex’s povetacicept meets primary endpoint in IgAN trial By Investing.com","https://uk.investing.com/news/company-news/vertexs-povetacicept-meets-primary-endpoint-in-igan-trial-93CH-4549066","3D AGO",{"id":149,"title":150,"source":151,"logo":32,"time":67},557579,"Vertex drug cuts proteinuria in Phase III IgA nephropathy trial","https://www.thepharmaletter.com/pharma-news/vertex-drug-cuts-proteinuria-in-phase-iii-iga-nephropathy-trial",{"id":153,"title":154,"source":155,"logo":5,"time":147},557612,"Vertex Pharmaceuticals Slides Despite Strong Kidney Trial Data","https://www.tipranks.com/news/catalyst/vertex-pharmaceuticals-slides-despite-strong-kidney-trial-data",{"id":157,"title":158,"source":159,"logo":5,"time":67},557578,"Vertex Pharmaceuticals: RAINIER Data Strengthen Best-in-Class IgAN Potential and Support Upside Beyond Durable CF Cash Flows","https://www.tipranks.com/news/ratings/vertex-pharmaceuticals-rainier-data-strengthen-best-in-class-igan-potential-and-support-upside-beyond-durable-cf-cash-flows-ratings-news?utm_source=marketbeat.com&utm_medium=referral",{"id":161,"title":162,"source":163,"logo":19,"time":147},557611,"Vertex Pharmaceuticals Stock Jumps After The Close: Here's Why","https://www.benzinga.com/trading-ideas/movers/26/03/51144402/vertex-pharmaceuticals-stock-jumps-after-the-close-heres-why",{"id":165,"title":166,"source":167,"logo":29,"time":67},557577,"Vertex rises after kidney drug meets goal in late-stage trial","https://www.bostonglobe.com/2026/03/09/business/vertex-rises-after-kidney-drug-meets-goal-late-stage-trial/",{"id":169,"title":170,"source":171,"logo":5,"time":147},557610,"Vertex’s povetacicept meets primary endpoint in IgAN trial","https://www.investing.com/news/company-news/vertexs-povetacicept-meets-primary-endpoint-in-igan-trial-93CH-4550506",{"id":173,"title":174,"source":175,"logo":35,"time":147},557606,"Vertex jumps after positive Phase 3 interim data for povetacicept in IgA nephropathy","https://www.quiverquant.com/news/Vertex+jumps+after+positive+Phase+3+interim+data+for+povetacicept+in+IgA+nephropathy",{"id":177,"title":178,"source":179,"logo":27,"time":67},557605,"Vertex eyes accelerated FDA nod for povetacicept with positive Phase III IgA nephropathy data","https://firstwordpharma.com/story/7131820",{"id":181,"title":182,"source":183,"logo":13,"time":147},557608,"Vertex Pharmaceuticals (VRTX) Reports Positive Phase 3 Trial Res","https://www.gurufocus.com/news/8691953/vertex-pharmaceuticals-vrtx-reports-positive-phase-3-trial-results",{"id":185,"title":186,"source":187,"logo":20,"time":147},557607,"Vertex Rises After Kidney Drug Meets Goal in Late-Stage Trial","https://www.bloomberg.com/news/articles/2026-03-09/vertex-rises-after-kidney-drug-meets-goal-in-late-stage-trial",{"id":189,"title":190,"source":191,"logo":13,"time":67},557602,"Vertex Pharmaceuticals (VRTX) Surges 7% Following Promising Tria","https://www.gurufocus.com/news/8692123/vertex-pharmaceuticals-vrtx-surges-7-following-promising-trial-outcomes",{"id":193,"title":194,"source":195,"logo":5,"time":67},557601,"BMO reiterates Vertex stock rating on strong IgAN trial data","https://www.investing.com/news/analyst-ratings/bmo-reiterates-vertex-stock-rating-on-strong-igan-trial-data-93CH-4550789",{"id":197,"title":198,"source":199,"logo":22,"time":67},557604,"Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy","https://www.tradingview.com/news/reuters.com,2026:newsml_FWN3ZX127:0-vertex-announces-positive-week-36-interim-analysis-results-for-primary-and-all-secondary-endpoints-in-the-rainier-phase-3-trial-of-povetacicept-in-adults-with-iga-nephropathy/",{"id":201,"title":202,"source":203,"logo":18,"time":67},557603,"RANIER: Povetacicept Achieves Primary and All Secondary Endpoints for IgAN","https://www.hcplive.com/view/ranier-povetacicept-achieves-primary-and-all-secondary-endpoints-for-igan",{"id":205,"title":206,"source":207,"logo":5,"time":147},557609,"Vertex Pharmaceuticals announces positive week 36 results in Povetacicept study","https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-week-36-results-in-povetacicept-study-thefly-news",{"id":209,"title":210,"source":211,"logo":5,"time":67},557600,"BMO reiterates Vertex stock rating on strong IgAN trial data By Investing.com","https://au.investing.com/news/analyst-ratings/bmo-reiterates-vertex-stock-rating-on-strong-igan-trial-data-93CH-4301617",{"id":213,"title":214,"source":215,"logo":26,"time":147},557759,"Vertex's kidney disease drug meets main goal in late-stage trial","https://www.aol.com/articles/vertexs-kidney-disease-drug-meets-201253807.html",{"id":217,"title":218,"source":219,"logo":31,"time":67},557758,"Vertex says its drug successfully reduced marker of kidney disease in late-stage trial","https://www.statnews.com/2026/03/09/vertex-iga-nephropathy-study-results/",{"id":221,"title":222,"source":223,"logo":23,"time":67},557757,"Vertex races to FDA after phase 3 kidney disease data impress analysts","https://www.fiercebiotech.com/biotech/vertex-races-fda-after-phase-3-kidney-disease-data-impress-analysts",{"id":225,"title":226,"source":227,"logo":16,"time":67},557590,"Vertex's $4.9B kidney disease bet hits key milestone","https://www.bizjournals.com/boston/news/2026/03/10/vertex-povetacicept-phase-3.html",{"id":229,"title":230,"source":231,"logo":15,"time":67},559494,"Here’s Why Vertex Pharmaceuticals Stock (VRTX) Is Up 10% Today","https://www.tipranks.com/news/heres-why-vertex-pharmaceuticals-stock-vrtx-is-up-10-today",{"id":233,"title":234,"source":235,"logo":12,"time":67},559495,"Vertex Reports Trial Results for a Kidney Drug. What It Means for the Stock.","https://www.barrons.com/articles/vertex-stock-kidney-drug-fda-bc6a4eeb?gaa_at=eafs&gaa_n=AWEtsqdM_3rnvBCGVW6neajpCvcG-k0OMHH1IzPhz1WkwOzpuu0dupAEaKDZ&gaa_ts=69b07d13&gaa_sig=U3bU0s9i6Lrr9UAvOrKlweffkcGXEVj2G4wKys4H4casXPBzF4wZSbPO2dgQx0L7rpRy6uos8xwVCLcKsyO5ZA%3D%3D",{"id":237,"title":238,"source":239,"logo":28,"time":67},557592,"Vertex Stock Pre-Market (+4.7%): Positive Phase 3 Kidney Drug Data","https://www.trefis.com/data/companies/VRTX/no-login-required/K9YjYY5f/Vertex-Stock-Pre-Market-4-7-Positive-Phase-3-Kidney-Drug-Data",{"id":241,"title":242,"source":243,"logo":11,"time":67},559492,"VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study","https://sg.finance.yahoo.com/news/vrtx-stock-gains-upbeat-interim-161400156.html",{"id":245,"title":246,"source":247,"logo":12,"time":67},557591,"Vertex Stock Jumps. What Wall Street Is Saying About Its Kidney Drug Trial.","https://www.barrons.com/articles/vertex-stock-kidney-drug-fda-bc6a4eeb?gaa_at=eafs&gaa_n=AWEtsqcsE_yCyHm34kA7zbI-Dli6_cK7N19JOq06mgJegsSpa6QscqgsKjZO&gaa_ts=69b00c8a&gaa_sig=V4prDesC5tW98scafybIUxCpvrrPYiadGsvHOhpJBRfF5_Hd44T_fHO0PJoRFYyx2-NtsjwGzESqfId6_OWeqQ%3D%3D",{"id":249,"title":250,"source":251,"logo":5,"time":67},559493,"Povetacicept Significantly Reduces Proteinuria in Adults With IgA Nephropathy","https://www.empr.com/news/povetacicept-significantly-reduces-proteinuria-in-adults-with-iga-nephropathy/",{"id":253,"title":254,"source":255,"logo":13,"time":67},559490,"Vertex Pharmaceuticals (VRTX) Rating Maintained, Price Target Raised by Morgan Stanley | VRTX Stock News","https://www.gurufocus.com/news/8695336/vertex-pharmaceuticals-vrtx-rating-maintained-price-target-raised-by-morgan-stanley-vrtx-stock-news",{"id":257,"title":242,"source":258,"logo":22,"time":67},559491,"https://www.tradingview.com/news/zacks:55199ce6e094b:0-vrtx-stock-gains-on-upbeat-interim-data-from-kidney-disease-drug-study/",{"id":260,"title":261,"source":262,"logo":10,"time":67},557598,"Vertex Pops On 'Remarkable' Late-Stage Results","https://www.investors.com/news/technology/vertex-stock-chronic-kidney-disease-iga-nephropathy/",{"id":264,"title":130,"source":265,"logo":5,"time":67},559458,"https://ng.investing.com/news/analyst-ratings/jefferies-initiates-vertex-stock-with-buy-rating-on-cystic-fibrosis-strength-93CH-2383691",{"id":267,"title":268,"source":269,"logo":5,"time":67},557597,"Wolfe Research reiterates Vertex stock rating on IgAN trial data By Investing.com","https://au.investing.com/news/analyst-ratings/wolfe-research-reiterates-vertex-stock-rating-on-igan-trial-data-93CH-4301645",{"id":271,"title":272,"source":273,"logo":17,"time":67},557599,"Vertex kidney disease drug hits mark in late-stage study","https://www.biopharmadive.com/news/vertex-povetacicept-iga-nephropathy-study-results/814253/",{"id":275,"title":90,"source":276,"logo":14,"time":67},557594,"https://whbl.com/2026/03/09/vertexs-kidney-disease-drug-meets-main-goal-in-late-stage-trial/",{"id":278,"title":279,"source":280,"logo":5,"time":67},557593,"Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints i","https://www.pharmiweb.com/press-release/2026-03-09/vertex-announces-positive-week-36-interim-analysis-results-for-primary-and-all-secondary-endpoints-i",{"id":282,"title":283,"source":284,"logo":14,"time":67},557596,"Vertex’s kidney disease drug meets main goal in late-stage trial","https://1027wbow.com/2026/03/09/vertexs-kidney-disease-drug-meets-main-goal-in-late-stage-trial/",{"id":286,"title":287,"source":288,"logo":5,"time":67},557595,"Wolfe Research reiterates Vertex stock rating on IgAN trial data","https://za.investing.com/news/analyst-ratings/wolfe-research-reiterates-vertex-stock-rating-on-igan-trial-data-93CH-4155264","#3aadc4ff","#3aadc44d",1773365459738]